The growing use of glucagon-like peptide-1 (GLP-1) receptor agonists and dual GIP/GLP-1 agonists has intensified debate over the role of pharmacotherapy in addressing obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.